Venus Remedies strengthens its foothold in the ASEAN, South America, and Eastern Europe regions with cancer drug approvals for marketing of essential cancer drugs in the Philippines, Paraguay, Georgia, and Moldova. The company now holds 506 marketing approvals across 76 countries, marking a milestone in its quest to become a top oncology medicine supplier from India in the ASEAN region.
Venus Remedies, a provider of affordable cancer drugs, has expanded its presence in the ASEAN, South America, and Eastern Europe regions by securing marketing authorizations for essential cancer drugs in the Philippines, Paraguay, Georgia, and Moldova. The company now has a total of 506 marketing approvals across 76 countries.
In the ASEAN region, Venus Remedies achieved marketing approval for topotecan in the Philippines, the second-largest market in the region. The company reinforced its position as a leading exporter of oncology drugs by registering products like irinotecan in Paraguay, docetaxel in Georgia, and topotecan and irinotecan in Moldova.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, “This accomplishment is a decisive move towards achieving our goal of emerging as the top oncology medicine supplier from India in the ASEAN region and further expanding the reach of our cancer drugs in South America and Eastern Europe. With these marketing authorizations, we will be able to further extend our operations to new markets and reaffirm our commitment to provide advanced cancer treatment options with improved outcomes for patients.”
The Philippine market, valued at $5 billion for pharmaceuticals, presents immense opportunities for Venus Remedies to expand its operations in the Asia-Pacific and Southeast Asia regions. With a focus on oncology products, the company has already submitted dossiers for over 50 marketing authorizations to the Philippine Health Ministry.
In Paraguay, a $431.9 million pharmaceutical market, the marketing authorization for irinotecan is expected to facilitate the registration process for Venus Remedies’ oncology drugs in other South American countries, leveraging similar regulatory processes.
Moreover, marketing authorizations for docetaxel in Georgia and topotecan and irinotecan in Moldova will enable the company to consolidate its position in Eastern Europe and the Balkan region. Recently, Venus Remedies secured its first marketing authorization from Bosnia for a chemotherapy drug.
Akshansh Chaudhary, Executive Director at Venus Remedies, emphasized the significance of these marketing approvals, stating, “These marketing approvals are testimony to our uncompromising quality standards. We will continue to leverage our expertise, regulatory might, and global partnerships to develop advanced therapies that can make a substantial difference in the lives of patients around the world.”
The recent expansion of Venus Remedies’ oncology wing through marketing approvals for key cancer drugs in the UK, Malaysia, Oman, Iraq, and now in the Philippines, Paraguay, Georgia, and Moldova demonstrates the company’s commitment to enhancing global accessibility to affordable and advanced cancer treatments.`
